The Importance of a Risk Based Approach in Implementing and Maintaining an Enterprise Wide Compliance Program

The Importance of a Risk Based Approach in Implementing and Maintaining an Enterprise Wide Compliance Program To be held on 23rd to 24th Jan 2014 at Hollywood, FL

 Course Description:

 The cost of non-compliance with regulatory BSA/AML standards within organizations has been great. Organizations have suffered irreparable reputational damage and have had to pay exorbitant regulatory fines in the millions for failing to implement and maintain strong compliance programs. It would be prudent to ensure your organization’s compliance program is effective and it is tailor-made in light of the key risk factors within your organization.

 This seminar will provide an overview of the importance of the risk based approach in implementing and maintaining an enterprise wide compliance program.

 This two day interactive workshop will also provide attendees:
 The basis of the risk based approach and the essential elements of an effective risk assessment.
 Transaction monitoring guidance, suspicious activity guidelines and independent testing techniques which would assist attendees in improving their companies overall compliance program.
 A detailed review of enforcement action case studies and how these could have been prevented
 Key internal controls that can help prevent and detect money laundering and terrorist financing
 Best practice tools on how to implement and maintain an enterprise wide Risk Based Approach (RBA) compliance program within your organization
 RBA Toolkit that will assist attendees to implement and maintain an effective enterprise wide compliance program

 Learning Objectives:

 To provide an understanding of the key elements of a risk based approach
 To effectively mitigate the money laundering and other financial crime risk within your organization
 To meet/exceed regulatory expectations and to ensure the organization is prepared to manage vulnerabilities of money laundering and other financial crimes
 To understand the holistic nature of the risk assessment which takes into account all business lines of the organization
 The course will focus on the following key aspects of an enterprise wide compliance program:
 Policies and Procedures
 Customer Due Diligence
 Transaction monitoring guidance
 Suspicious Activity Reporting guidelines
 Ongoing Due Diligence
 Adequate training
 Independent testing techniques
 Senior Management Oversight

 For more information kindly visit :  http://www.companyprofilesandconferences.com/seminars-conferences/Conference-c42/The-Importance-of-a-Risk-Based-Approach-in-Implementing-and-Maintaining-an-Enterprise-Wide-Compliance-Program.html                                 

 Or

 Contact us at :

 Company Profiles And Conferences
 Mob +919223375060 / 919223767111
 Fax : +91 22 27810778
 E-mail : info@companyprofilesandconferences.com
 Website : www.companyprofilesandconferences.com
 

Medical Device - QSR Compliant Product Development Process

Medical Device - QSR Compliant Product Development Process To be held on 23th to 24th Jan 2014 at San Francisco, CA

 Course Description:

 Integrating the requirements of 21 CFR 820 into a product development process is challenging. Done poorly, it drags down the design process and puts you at risk. Done well, it delivers quality products, resource efficiencies and compliance that are easily demonstrated to the FDA.

 You can’t afford to be in a position where either design controls or the product development process are weak. Design controls are essential to safety and effectiveness. The FDA reports ineffective design controls are the root cause of as many as 31% of recalls. Ineffective product development processes are slow, costly and often miss significant business objectives.

 This seminar on quality system regulations for medical devices market will show you how to build a best practice stage gate product development process that not just incorporates 21 CFR 820 design controls but keeps you ahead of the competition and easily shows compliance during an audit. The process showcased in this course will also fulfill QSR requirements, produce the objective evidence necessary to prove compliance, manage resources and deliver quality products.

 Learning Objectives:
 The seminar will focus on understanding:
 The key elements of 21 CFR 820 design controls
 Best practice stage gate product development
 How 21 CFR 820 design controls can be integrated into a stage gate product development process
 How to link to intended use, user needs, risk management and manufacturing processes
 How to manage both new product development and design changes
 How to manage marketing, costs and schedule requirements in parallel with the regulatory processes
 How to systematically create the required objective evidence and how to easily produce it during an audit

 For more information kindly visit :  http://www.companyprofilesandconferences.com/seminars-conferences/Conference-c42/Medical-Device-QSR-Compliant-Product-Development-Process.html                              

 Or

 Contact us at :

 Company Profiles And Conferences
 Mob +919223375060 / 919223767111
 Fax : +91 22 27810778
 E-mail : info@companyprofilesandconferences.com
 Website : www.companyprofilesandconferences.com

 

Seminar on Issues of Employees, Workers Compensation, and Military Leave To be held on 5th to 6th Dec 2013 at Dallas/Fort Worth, TX

Seminar on Issues of Employees, Workers Compensation, and Military Leave To be held on 5th to 6th Dec 2013 at Dallas/Fort Worth, TX

 Course Description:
 This interactive one and a half day seminar will unravel complex issues such as employee leaves of absence, health issues, family issues, pregnancy, military duties, and workplace injuries. Attendees will get insight into the practical and legal issues involved in managing employee attendance, leaves of absence, and workplace accommodation requirements.

 The purpose of this interactive course is to give you a real working knowledge of how to handle the most difficult workplace situations such as handling chronic ailments. You will have plenty of time to ask questions and have hands-on problem-solving experience. An experienced employment law attorney will guide you through what to say (and not to say) when engaging in the “interactive process,” when and how to grant leave, and when you can safely say, “we’re done.”

 Learning Objectives:
 Get comfortable with the most up-to-date Federal and Texas laws governing employee leaves of absence, health issues, family issues, pregancy, military duties, and workplace injuries.
 Learn what to do when an employee says, “I’m having trouble doing this job because of my health”.
 Know the procedures and forms to use when an employee says, “I’m can’t come to work” for an hour or a month.
 Learn what to do when an employee has a physical or mental breakdown at work.
 Practice techniques to use (and not use) when you suspect fraudulent use of leave.
 Learn how your current sick leave and absence control policies correspond with (and sometimes violate) the latest laws.
 Feel confident when you finally decide that you have reached the end of your obligations toward an employee who can’t come to work or can’t perform the job.

 KEY SPEAKER

 Sheila Gladstone heads up Lloyd Gosselink’s Employment Law Practice Group and has over 25 years' experience assisting employers with all aspects of employment law. Ms. Gladstone is a frequent and entertaining speaker and a published author on a variety of employment-related issues. She uses a direct approach and gives practical advice to help employers deal with personnel issues and employment regulations, so they can focus on their core business. She believes employees should contribute to, not hinder, the growth of the business or the mission of the agency. She was among the five percent of Texas attorneys selected for the 2012 and 2013 Texas Super Lawyers list, which recognizes outstanding professional achievement.

 For more information kindly visit :  http://www.companyprofilesandconferences.com/seminars-conferences/Conference-c42/Managing-Employee-Leaves-Health-Issues-Disability-and-Job-Accommodation-A-Practical-Guide-to-the-ADA-FMLA-Workers-Compensation-and-Military-Leave-One-and-a-Half-Day-In-Person-Seminar-.html                               

 Or

 Contact us at :

 Company Profiles And Conferences
 Mob +919223375060 / 919223767111
 Fax : +91 22 27810778
 E-mail : info@companyprofilesandconferences.com
 Website : www.companyprofilesandconferences.com

Acceptance Sampling - The Total Picture To be held on 5th to 6th Dec 2013 at Philadelphia, PA

Acceptance Sampling - The Total Picture To be held on 5th to 6th Dec 2013 at Philadelphia, PA

 How well do you understand sampling plans and their application in your company? Many companies have procedures and program that fall short of the regulatory requirements and good statistical practice. In some cases, FDA may give the firm a 483 or even a Warning Letter. In other cases, the firm may not use the best methods, resulting in waste of resources.

 This unique hands-on course will provide attendees with a solid understanding of acceptance sampling methods and their application to medical device manufacturing. The course delivers tools, templates, and insight that will allow participants to implement sampling methods within their firm.

 This two-day hands-on course provides a clear understanding of the underlying statistics used in acceptance sampling. The course uses exercises to solidify understanding. As part of the practical implementation, the course explains common standards such as Z1.4 for attribute sampling and Z1.9 for variables sampling. In addition, the course covers other, less well known, methods such as sequential sampling, continuous sampling, and chain sampling.

 The course also covers specific applications of sampling including incoming inspection, design validation, design verification, process validation, and quality audits.

 Learning Objective:

 Upon course completion, participants will:

 Understand FDA QSR and ISO 13485 requirements for acceptance sampling
 Perform calculations using the binomial distribution
 Perform calculations using the hypergeometric distribution
 Perform calculation using the normal distribution
 Apply tests of normality to a data set
 Understand Acceptable Quality Limit (AQL) and apply it
 Understand Operating Characteristic (OC) curves
 Select sampling plans from Z1.4
 Select sampling plans from Z1.9
 Implement sequential sampling plans (using the Wald method)
 Implement continuous sampling plans (CSP)
 Implement skip-lot sampling plans (SkSP)
 Implement chain sampling plans (ChSP)

 For more information kindly visit :  http://www.companyprofilesandconferences.com/seminars-conferences/Conference-c42/Acceptance-Sampling-The-Total-Picture.html                             

 Or

 Contact us at :

 Company Profiles And Conferences
 Mob +919223375060 / 919223767111
 Fax : +91 22 27810778
 E-mail : info@companyprofilesandconferences.com
 Website : www.companyprofilesandconferences.com
 

Managing an Effective AML Compliance Program To be held on 5th to 6th Dec 2013 at Phoenix, AZ

Managing an Effective AML Compliance Program To be held on 5th to 6th Dec 2013 at Phoenix, AZ

 Course Description:
 
 Are the financial transactions within your organization subject to money laundering risk? Do you have a robust internal controls program that focuses on mitigating the greatest AML/Fraud risks? Are your employees aware of the red flags within all financial transaction business processes and know what to do if they find unusual or suspicious activity? Are your company and management are up to date on its compliance requirements and the potential impact of non-compliance?

 Whether you need to get back-to-basics or you are a seasoned AML professional, join us as we explore the many facets of managing an effective AML compliance program: Join us as we focus on the following key elements:

 Regulatory frameworks surrounding anti-money laundering
 Objectives of an effective AML compliance program
 Risk assessing your institution
 Developing robust internal controls
 Training for appropriate personnel
 Expectations and duties of the appointed compliance officer
 Effective audit program to ensure adequacy of your AML compliance program

 Learning Objective:

 Key goals of this course are:

 To provide an understanding of money laundering and how it can impact an institution
 To review the importance of “tone at the top” and how to implement a compliance-friendly environment
 To learn about the critical internal controls and how these controls can protect your institution
 The course will focus on the 4 pillars of an AML compliance program:
 Policies, procedures and internal controls
 Designation of a compliance officer
 Training for appropriate personnel
 Independent audit
 To understand the importance of the risk assessment
 To focus on the senior management/board of directors oversight of the Program
 To discuss customer due diligence and know your customer expectations
 To discuss knowing your high risk customers
 To review implementation steps for enhanced customer due diligence
 To discuss red flags indicating unusual or suspicious activity
 To understand detection and reporting requirements under the Bank Secrecy Act
 To discuss recent case studies

 For more information kindly visit :  http://www.companyprofilesandconferences.com/seminars-conferences/Conference-c42/Managing-an-Effective-AML-Compliance-Program-.html                             

 Or

 Contact us at :

 Company Profiles And Conferences
 Mob +919223375060 / 919223767111
 Fax : +91 22 27810778
 E-mail : info@companyprofilesandconferences.com
 Website : www.companyprofilesandconferences.com
 

2 day Training on Fraud and Risk (Self) Assessments Using Process Mapping and Documentation, Questionnaires and Root Cause Analysis

2 day Training on Fraud and Risk (Self) Assessments To be held on 4th to 5th Dec 2013 at Dubai, UAE

 “In any business endeavor, if you don’t know exactly what to do or how to do something, it gets complicated really fast- and you waste a lot of time and money.”Joan Pastor, PhD
 A number of different approaches to risk assessment have been developed, yet companies face challenges in deciding which approach to take: a method that brings benefits to one may not be good enough for another. An important part of assessing risk and the effectiveness of controls is knowing exactly how to maximize the power of business, strategic, IT, operation, financial, assurance, tangible and intangible processes. Efficient and effective processes are the lifeblood of an organization. Research shows that 95% of people in any organization want to do well, but 95% of the processes in an organization are the key cause for an organization’s failure due to certain specific bad risks and deliberate fraud and wrongdoing.

 This concrete, hands-on, applications-focused two day program has consistently been one of the most popular courses in the world for the audit, risk management and finance professions or anyone who is trying to gather, prioritize and analyze the real threats to the business, and controls that will really work. Dr. Joan Pastor collaborated originally with several large telephone companies in the US to develop this course, and it has been continually updated as issues related to Governance, Risk and Compliance (GRC), Fraud, ERM and Risk Assessment, and the impact of IT to organizational systems evolve. There are a number of things that will make this course extremely useful and very different from any other training you have had in this area so far. These include:

 Focusing on getting the information from all levels of the workforce. In other words, from your Executive Committee and Board of Directors to any function in your organization, the information- and the analysis and decisions- will come from them, not you. Of course, you will actually have a strong influence, but in such a way that they will welcome your input and want your expertise.
 Learning how to conduct Fraud and Risk Organizational Assessments (FROA) at the executive and/or management levels (usually your most resistant people) of your organization and vastly increasing your influence with these people;
 Teaching the elusive concepts of risk, controls, residual risk, root cause analysis and so much more in such a concrete and easy to understand way that your clients finally completely understand it, really and truly understands how this information is great value to their own work, and want to tell you real (potential) risks and fraud;
 How to design and use questionnaires (and when NOT to use them) so that you get accurate information you can apply in numerous ways;
 Learning hundreds of strategies for influencing others, gaining “buy-in” to changes your clients need to make and for developing a truly collaborative relationship. You can, and will, be able to change what is often an adversarial relationship (or a disinterested party) into a true working relationship that benefits the whole company.

 For more information kindly visit :  http://www.companyprofilesandconferences.com/seminars-conferences/Conference-c42/2-day-Training-on-Fraud-and-Risk-SelfAssessments-Using-Process-Mapping-and-Documentation-Questionnaires-and-Root-Cause-Analysis.html                            

 Or

 Contact us at :

 Company Profiles And Conferences
 Mob +919223375060 / 919223767111
 Fax : +91 22 27810778
 E-mail : info@companyprofilesandconferences.com
 Website : www.companyprofilesandconferences.com
 

Conference on Downstream Oil & Gas

Conference on Downstream Oil & Gas To be held on 27 September 2013 at India Habitat Centre, New Delhi

 Conference Description

 As you must be aware, the Indian Petro Group is India’s leading news, information and market intelligence provider in the Indian oil & gas, power, fertilizer and petrochemical sectors through its websites indianpetro.com, indianfertilizer.com, energylineindia.com, indianpetrochem.com and IndianPetrochem.com. It delivers accurate, exclusive and independent sector specific information through its portals. As an extension of our work in these knowledge intensive sectors and in order to bring in more value to our clients, we have begun an Outreach Program aimed at direct one-on-one interface with various stakeholders in the sectors.

 The Downstream Oil & Gas Sector in India is under throes of a massive expansion, IndianOil refineries have an ambitious growth plan with an outlay of about Rs. 55,000 crore for capacity augmentation, de-bottlenecking, bottom upgradation and quality upgradation. Major projects under implementation include a 15 MMTPA grassroots refinery at Paradip, Orissa, Naphtha Cracker and Polymer Complex at Panipat, Panipat Refinery expansion from 12 MMTPA to 15 MMTPA, among others.
 Reasons and Benefits to Attend:

 We understand that you already have a robust business development plan underway and are hard pressed for time. However having a focussed audience involving individuals who have had many decades of experience in downstream industry can amplify your efforts and give you a head start in your company’s growth and expansion.

 A unique networking opportunity with the senior executives of Procurement and Materials Management in the Refinery and Pipelines Division of IOCL.
 Hearing their development plans for the forthcoming years.
 Getting an insight into dynamics of downstream sector in India
 Future planning for the upcoming projects and tenders from IOCL
 Unique opportunity to exhibit your products and services.
 Tracking recent developments in the downstream sector and how they affect you.
 Noting and discussing the issues and concerns through open discussion panels

 Who Should Attend:

 Equipment manufacturers, Investment Banks, Foreign Companies looking for Investment Opportunities, Consulting Companies. Banks & Legal firms, Policy & Decision Makers, Overseas Technology Provider, Service providers, Consulting Companies, Investment Banks, Researchers, Government & Regulation Bodies, Logistics Companies
 
 For more information kindly visit : http://www.companyprofilesandconferences.com/seminars-conferences/Energy-Resources-c3/Conference-on-Downstream-Oil-Gas.html                               

 Or

 Contact us at :

 Company Profiles And Conferences
 Phone: +919223375060 / 919223767111
 Fax: +91 22 27810778
 Email : info@companyprofilesandconferences.com
 Website : www.companyprofilesandconferences.com/

2nd Annual Mobile Apps 2013

2nd Annual Mobile Apps 2013 To be held on 30th August 2013 at Matthan Hotel, Bangalore, India

 The global mobile industry is witnessing volatile growth for last couple of years. Advancement of mobile technology, improved infrastructure and Smartphone revolution have allowed people to perform much more with their mobile phones than ever before. This has resulted in an exponential demand and growth of mobile applications.

 The mobile app market is thriving to great heights. More than hundreds of handsets are capable of installing and running apps and a swerve of big-name app stores are striving to compete. It is expected that the market for mobile applications will be "as big as the internet", peaking at 10 million apps in 2020.

 Presently India having over 800+ million mobile connections and 50-150m mobile internet users it is evident mobile apps are becoming very popular. By 2015 India is expected to have 237 million mobile internet “activated” connections. Entrepreneurs are focusing a lot on mobile apps which are internet rather than SMS based. Mobile App Stats in India - 100 million apps being downloaded in India every month. India’s app developer base is estimated at 250,000.

 With world’s foremost brands recognizing the need of their presence in at least one of the top applications stores and the average mobile application per brand rising over 25 (for top 100 brands, 250 in case of media companies globally); the mobile applications market has took new role in defining the marketing strategy of businesses. This has opened up new horizons for already booming mobile applications market and provides faster acceleration for the market. Though these global brands do not look to make money directly with apps; however, the apps are adding up their brand equity. The surge in number of app stores and availability of multi-platform apps has also reshaping the future of the market. The excitement around mobile applications is going to have a major impact on our economy, and our way of life.

 Key Speakers:-

 Ochintya Sharma, Vice President, Samsung India
 Raghavan Subramanian, Associate Vice President, Infosys Labs
 Anand Subbaraman, Senior Director, Product Strategy, Oracle
 Pragati Ogal Rai, Mobile Technology Evangelist, PayPal (North America)
 Vineet Durani, Director - Windows Phone Business Group, Microsoft
 Vikram Srinivasan, Director, Alcatel-Lucent Bell Labs
 Praful Bhoyar, Portfolio Director, Dell
 Udayan Banerjee, VP, NIIT Technologies
 Sudeendra Koushik, Practice Director, HCL Technologies
 Jeffrey Rufus, Head - Nokia App Store & Windows Marketplaces, Nokia
 Uttam Kumar, Head – New Technologies Innovation & Incubation – IT, Aircel
 Viswanath Poosala, Head of Bells Labs – India, Alcatel-Lucent
 Sridhar T. Pai, CEO, Tonse Telecom
 Prakash Sayini, Founder and Managing Director, MobiDex360 Solutions

 For more information kindly visit : http://www.companyprofilesandconferences.com/seminars-conferences/Mobile-Telecoms-c14/2nd-Annual-Mobile-Apps-2013.html                              

 Or

 Contact us at :

 Company Profiles And Conferences
 Phone: +919223375060 / 919223767111
 Fax: +91 22 27810778
 Email : info@companyprofilesandconferences.com
 Website : www.companyprofilesandconferences.com/
 

2nd Annual Pharma Anti-Counterfeiting Congregation 2013

2nd Annual Pharma Anti-Counterfeiting Congregation 2013 To be held on 8th and 9th october 2013 at Hilton Hotel, London, UK

CONFERENCE INTRODUCTION:-

Counterfeit Pharmaceuticals do not only provoke immense economic damage to pharmaceutical companies but are a great risk to the public. The increasing threat calls for immediate action against counterfeit medicines. Steps must be taken by governmental and international authorities as well as by every single affected pharmaceutical company. Counterfeit APIs and medicines pose a growing threat to patients worldwide, with increasing numbers in Europe and the USA. Customs all over the world find more and more illegally produced drugs. Moreover, drugs are increasingly sold via the Internet making it much easier to put counterfeits into circulation.

Counterfeiting of drugs and medical devices cost the pharmaceutical and medical device industry billions of dollars annually in lost revenues. This loss is amplified by the serious threats fake drugs pose to the health and safety of consumers. Directing your organization toward an successful brand protection system can be a daunting task given the sophistication of counterfeiters and the difficulty in tracking and prosecuting perpetrators. This in-depth workshop will teach you how to ensure you have a solid counterfeit program and help you to gain a better understanding of how to develop an efficient brand protection program. It is estimated that counterfeiting is a $600 billion a year problem. In fact, it's a problem that has grown over 10,000% in the past two decades, in part fuelled by CONSUMER DEMAND. The real truth is people who purchase counterfeit merchandise risk funding nefarious activities, contributing to unemployment, creating budget deficits and compromising the future of this country in the global economy.

WHY SHOULD YOU ATTEND:-

“2nd Annual Pharma Anti-Counterfeiting Congregation 2013 - Competences to Combat Counterfeits”

Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading companies showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.

KEY THEMES DISCUSSED AT THIS CONFERENCE:-

• Anti-Counterfeiting and Product Security in EU and USA: government policies & strategies
• Identifying current developments in counterfeits & ways to overcome threats
• Discovering successful business models - Opportunities & Challenges
• Identify main challenges and methods to improve global security
• International partnerships and EU & U.S. regulations to combat counterfeit medicines
• Practical Tips - Strategies for securing the supply chains of the 21st century - authentication, digital serialization, track and trace technologies and government enforcement And Many more...
Key Speakers Include:-
Wendy Greenall, EMEA Counterfeit Medicines Laboratory Manager, Pfizer
Steven Gore, AIDC Programme Lead, NHS
Tomazs Dzitko, CEO, Delfarma
Janice Kite, Traceability Director Healthcare, GS1 Global Office Healthcare
Phil Lewis, International Cooperation & Legal Affairs Department, Cooperation Programmes Service, University of Texas (USA)
Marv Shepherd, Director, Center for Pharmacoeconomic Studies, College of Pharmacy, University of Texas (USA)
Jose Henrique Vasi Werner, Partner, Dannemann Siemsen Advogados (Brazil)
Christoph Krahenbuhl, Managing Director, 3C Integrity
Prashant Yadav, Director of Healthcare Research, William Davidson Institute (Michigan, USA)
Mark Davison, CEO, Blue Sphere Health, Acting Chief Business Officer,PharmaSecure
Alex Hall, CEO, QPQuandary (Former Quality Unit Manager,  Roch

For more information kindly visit : http://www.companyprofilesandconferences.com/seminars-conferences/Pharmaceuticals-Healthcare-c13/2nd-Annual-Pharma-Anti-Counterfeiting-Congregation-2013.html                              

Or

Contact us at :

Company Profiles And Conferences
Phone: +919223375060 / 919223767111
Fax: +91 22 27810778
Email : info@companyprofilesandconferences.com
Website : www.companyprofilesandconferences.com/

Pharmaceutical Nanotechnology Congregation 2013

CompanyProfileandconferences.com promote a new conference "Pharmaceutical Nanotechnology Congregation 2013" from which you can Learn from the experts on the technical, quality, and regulatory considerations of nanotechnology.

 Pharmaceutical Nanotechnology Congregation 2013 To be held on 15th-16th October 2013 at Hilton Hotel, London, UK

 Nanotechnology has supported breakthrough innovation across many industries especially Pharmaceutical. Nanotechnology brings revolutionary changes in the field of life sciences including drug delivery, diagnostics, nutraceuticals and production of biomaterials. Pharmaceutical industry is facing unique pressure in bringing out their products to the market quicker and with a higher probability of success. Nanotechnology presents a possibility for all pharmaceutical companies to improve upon existing safe therapies and enjoy patent protection or significant increase the bioavailability of new molecular entities in development. Understanding the technical and regulatory hurdles necessary to safely and effectively leverage nanotechnology is the first step to realizing the potential benefits of this approach. Moreover, many pharmaceutical companies have begun exploiting nanotechnology in improving drug delivery and targeting. In oncology, for instance, nanomedicines are being tested for their ability to reach cell targets that have otherwise eluded more conventional medicines.

 Nanomaterials have been increasingly recognized as a promising component of the future of biotechnology and biomedicine. The global market for nanomedicine was valued at $72.8 billion in 2011 and is projected to grow at a robust compound annual growth rate (CAGR) of 12.5%, reaching $130.9 billion by 2016. The overall anticancer nanomedicine market reached $28 billion in 2011, up from $16.4 billion in 2006, a 71% increase. It is expected to reach $46.7 billion by 2016, a CAGR of 10.8% between 2011 and 2016.

 Yet, the nature of this scientific advancement remains surrounded by “unknown unknowns.” And there is a need for companies—in the pharma sector and beyond—to be proactive in the management and communication of this technology. So for pharmaceutical companies, the question is not, “Is nano a stakeholder concern?” but rather, “What do we need to learn, and then what do we need to show our stakeholders to gain their trust?”

 Due to the variety of potential applications (including industrial and military), governments have invested billions of dollars in nanotechnology research. Through its National Nanotechnology Initiative, the USA has invested 3.7 billion dollars. The European Union has invested 1.2 billion and Japan 750 million dollars.

 Key Speakers:-

 Marianne Ashford, Drug Delivery – Principal Scientist, AstraZeneca
 Sumit Munjal, EU Medical Advisor & Pharmacovigilance Director, Global Safety - Oncology Portfolio, Takeda
 Tom Kurzawinski, Consultant Pancreatic and Endocrine Surgeon, University College London Hospitals - NHS Foundation Trust, Royal Free Hospital
 Sanyogitta Puri, Senior Scientist - Medicines Evaluation, Pharmaceutical Development, AstraZeneca
 Milos Todorovic, Lead Analyst - Practice Leader, Lux Research (Boston, USA)
 Helen Townley, Senior Research Fellow - Dept. Engineering Science, Oxford University
 Brij Patel, CEO, RegExcelconsulting (Former Biological Assessor, MHRA)
 Ijeoma F. Uchegbu, Chair in Pharmaceutical Nanoscience, Department of Pharmaceutics, UCL School of Pharmacy
 Twan Lammers, Head of work groups - Department of experimental molecular imaging, University of Twente (Germany)
 Jeffrey H. Rosedale, Partner, Woodcock Washburn (Philadelphia)
 Peter Bogaert, Managing Partner, Covington & Burling (Belgium)

 For more information kindly visit : http://www.companyprofilesandconferences.com/seminars-conferences/Pharmaceuticals-Healthcare-c13/Pharmaceutical-Nanotechnology-Congregation-2013.html                             

 Or

 Contact us at :

 Company Profiles And Conferences
 Phone: +919223375060 / 919223767111
 Fax: +91 22 27810778
 Email : info@companyprofilesandconferences.com
 Website : www.companyprofilesandconferences.com/
 

Pre-Filled Syringes Congregation 2013

CompanyProfileandconferences.com promote a new conference which provides “Successful Strategies, Safety Inspection, Packaging, Regulatory Compliance & Commercialisation of Pre-Filled Syringes for the emerging market”

 Pre-Filled Syringes Congregation 2013 To be held on 25th-26th June 2013 at Hilton London Euston, London, UK

 The drug delivery and packaging industries are rapidly expanding, with pre-filled syringes alone predicted to exceed $4.0bn by 2015. Pre-filled syringes constitutes one of the fastest growing markets in the drug delivery and packaging sectors with total revenues in this market expected to reach $5.5bn in 20251. It continues to offer one of the highest growth potentials in the pharmaceutical industry with 20% CAGR over the past 5 years. This is driven by a marked rise in the success of biological drugs and vaccines market, which requires the drug to be injected directly into the bloodstream.

 This helps facilitate absorption compared to oral delivery, which results in the drug being degraded in the stomach or metabolized by the liver before it is circulated systemically. It's difficult to reproduce these benefits with other drug delivery systems so it is unlikely to be replaced anytime soon. With the prospect of easier administration, reduced risk of detrimental occurrences and cost-effectiveness, its no wonder Pre-filled syringes Market are fast becoming the drug delivery system of choice. The continued focus of the pharmaceutical industry on biologics will mean there will be continued demand for this delivery method into the future. Pre-Filled Syringes 2013 will look at key areas including device development and the design concept; secondary packaging and quality assurance; site design and regulation and will deliver vital advice on how to create strategies for future commercial success. Delivering an in-depth market overview, whilst delivering perceptive looks into regulatory considerations, formulations and sterilization

 KEY THEMES DISCUSSED AT THIS SUMMIT:-

 How should the industry approach the rapidly emerging and developing pre-filled syringes?
 How are policy makers shaping the contours of pre-filled syringes, and what implications they have for current biologic drug development and patent protection?
 Discover new developments in the technology used to make pre-filled syringes
 Commercial challenges and opportunities - strategies to develop pre-filled syringes
 Opportunities for outsourcing of pre-filled syringes, challenges faced and cost effectiveness
 Learn to implement best practices through recent successful strategies and business models – real time case studies
 Learning the latest novel technologies in filling, closing and secondary packaging
 Analysing all phases of facility design and understand the requirements of pre-filled syringes development lines
 Primary container developments - Glass Vs Plastic
 Risks in terms of filling techniques - volume, viscosity, foaming, trapped air in the syringe
 Ascertaining the volume and level of safety that will be required to prove patient safety and efficacy to facilitate approval
 Inspection technologies are available to ensure validity and quality of pre-filled syringes to ensure safety and regulatory compliance
 Understanding the current regulatory and commercialisation considerations for Pre-Filled Syringes 2013 in Europe and the US
 Be part of a major networking opportunity

 WHO SHOULD ATTEND:-

 Presidents, Chief Executives, Chief Scientific Officers, Chief Operating Officers, Senior Vice Presidents, Vice Presidents, Heads, Senior Directors, Directors, Clinicians, Principal Scientists, Principal Investigators, Managers, Project/Team Leaders:

 Parenteral drug delivery, Drug Delivery, Vaccines, Packaging, Devices, Labelling, Manufacturing, Sterilisation, Sterile process systems, Technical support, Pharmaceutical formulation, Product design, Research and development, Drug discovery and delivery, Drug product process development, Drug device process development, Drug device safety, Regulatory affairs, Quality assurance, Quality control, Supply chain and procurement, Business development, Strategic alliances,Clinical product resourcing, Contract management, Investment and venture capital

 For more information kindly visit : http://www.companyprofilesandconferences.com/seminars-conferences/Conference-c42/Pre-Filled-Syringes-Congregation-2013.html                            

 Or

 Contact us at :

 Company Profiles And Conferences
 Phone: +919223375060 / 919223767111
 Fax: +91 22 27810778
 Email : info@companyprofilesandconferences.com
 Website : www.companyprofilesandconferences.com/

7th Cloud Computing Summit 2013

7th Cloud Computing Summit 2013 To be held on 9th July 2013 at Taj Vivanta - MG Road, Bangalore, India

 Cloud Computing has become one of the hottest IT enterprise topics of recent times. It is fast becoming mainstream with large steps being made in a relatively short period of time. Cloud Computing has become a scalable services consumption and delivery platform in the field of Services Computing. The technical foundations of Cloud Computing include Service-Oriented Architecture (SOA) and Virtualizations of hardware and software. The goal of Cloud Computing is to share resources among the cloud service consumers, cloud partners, and cloud vendors in the cloud value chain. The resource sharing at various levels results in various cloud offerings such as infrastructure cloud (e.g. hardware, IT infrastructure management), software cloud (e.g. SaaS focusing on middleware as a service, or traditional CRM as a service), application cloud (e.g. Application as a Service, UML modelling tools as a service, social network as a service), and business cloud (e.g. business process as a service).

 According to IDC, within just a few years, cloud computing has reshaped the IT marketplace and the way that organizations acquire and use IT products and services, disrupting their strategies and forcing them to reevaluate all of their alternatives to the status quo. Now the use of cloud computing is accepted as mainstream, this disruption is creating new opportunities for suppliers and catalyzing major changes in traditional.

 7th Cloud Computing 2013 is the only event focused on how traditional enterprises can adopt cloud computing models, featuring panels of thought leaders, candid conversations with industry luminaries. The conference is a reality check to better understand enterprise cloud computing. Cloud computing is big news, promising unlimited capacity and pay-as-you-go economics, plus connections to an always-on world. Enterprises are excited about cloud computing but little of it is ready to use yet. Clouds present security risks, and many enterprise applications have to be completely rewritten to run on scalable clouds. Forward-thinking business leaders are using the cloud within their enterprise data centers to take advantage of the best practices that cloud computing has established, namely scalability, agility, automation, and resource sharing. Although the term 'cloud computing' is relatively new, the technologies that make it possible have been used for some time.

 For example, cloud computing is enabled by grid computing, virtualization, utility computing, hosting and software as a service (SaaS). Virtualization is driving a fundamental shift in how we think about data center environments. It is lowering capital and operational costs, enabling IT agility, underlying Green IT initiatives and fuelling the cloud. This conference helps us to be aware of this paradigm shift and discusses the benefits of virtualization.

 This Cloud Computing conference is the place to meet all the key decision makers from all of the Cloud service providers in one place. This conference will address the current state of the market, the business value of the cloud, deployment strategies and integration techniques,security and privacy issues and will take a look into what the future holds for Cloud Computing.

 It gives us immense pleasure in welcoming you to the 7th Cloud Computing 2013

 Key themes discussed at this Summit:

 • Identifying current trends of Cloud Computing environment and how can you take advantage of the global market – Opportunities and Challenges
 • The Changing role of IT with the Cloud
 • Discovering successful business models for cloud computing - Cloud Gaming and Cloud TV
 • Rise of big data in your organisation - Making better informed decisions for your organisation
 • Creating new value chain and eco-system of mobile cloud computing
 • Driving telcos role in cloudscape – Understanding landscape of mobile cloud Computing
 • Best practice - Virtualization strategy
 • Discover why Cloud Computing is perfect for SME’s - Key advantages of cloud hosting for SMEs
 • Infrastructure, Deployment, Integration & Monetizing the Cloud business
 • How to move your business to cloud computing - practical tips
 • Learn from the industry leaders and emerging players offering to Cloud and SaaS space
 • Avoiding potential pitfalls in Cloud Computing and to improve your clients relationships
 • Optimising Cloud Computing Operation effectiveness for successful ROI
 • Best Practices for Business Data Storage & Backups
 • Tangible benefits & risk of moving to the cloud –security/compliance/data risks
 • SaaS, PaaS, IaaS - Present & Future outlook
 • Cloud Concerns and the Future – Where are we heading with this cloud era?
 • Network in our combined exhibition and catering area
 • Evening networking reception for all attendees

 For more information kindly visit : http://www.companyprofilesandconferences.com/seminars-conferences/Technology-c29/7th-Cloud-Computing-Summit-2013.html                           

 Or

 Contact us at :

 Company Profiles And Conferences
 Phone: +919223375060 / 919223767111
 Fax: +91 22 27810778
 Email : info@companyprofilesandconferences.com
 Website : www.companyprofilesandconferences.com/

5th Annual EPC Contracting Conference Summit 2013

EPC- The Changing Scenario: It is a must attend event for senior finance decision makers, taxation, legal and commercial professionals from large domestic and multinational EPC / Infrastructure companies & owner companies in India. The purpose of the event is to network, discuss and debate key tax legal and other policy developments."

BACKGROUND

Sub-Group on Infrastructure for 12th Five year plan (2012-17) has estimated US$ 1 trillion (approx) investments requirement for infrastructure sector over the next five year to sustain and boost the current GDP. 5th Annual EPC Contracting Conference Summit 2013

As the government is getting aggressive on reforms, there are more to come. India is capable of high growth and that large infrastructure projects are one of the areas of focus. The negative perception of India caught in policy logjam is changing as political support is increasing credibility of government policies

Among other initiatives, in December 2012, Cabinet Committee on Investment (CCI) has been set up under chairmanship of Prime Minister and comprises members from various ministries to facilitate speedy implementation of large scale projects. CCI has started meeting and is expected to facilitate the project approvals, etc. Almost, all the large projects will involve Engineering, Procurement and Construction (EPC) contracting.

It may be noted that tax is one of the key aspect which needs due attention while contracting EPC projects. It is pertinent to note that, each EPC contract is unique in terms of size, scale, complexity, content of offshore services and supplies, location of performance, etc. Further, each EPC contract involves multiple taxes and levies.

For more information kindly visit :   5th Annual EPC Contracting Conference Summit 2013                  
 

Conferences on 3rd Biosimilars Congregation 2013

3rd Biosimilars Congregation 2013 To be held on 9th April 2013 at Hyatt Regency, Mumbai 

 India is one of the biggest sources of biosimilars and is also an emerging market for biosimilars with its high population and investment in technology. It can emerge as one of the leaders in global biologic development by the end of this decade According to Global Industry Analysts Inc.. The global biopharmaceutical market was valued at $138 billion in 2012 and is expected to grow to over $320 billion by 2020. A research predicts that annual revenues for biopharmaceuticals have been rising year on year since 2001. In 2011, biopharmaceuticals accounted for 15.6% of the total pharmaceutical market.

 The next decade could see a paradigm shift in biomanufacturing technologies, including improvements in equipment efficiency and the introduction of novel therapies. In particular, disposable bioprocessing equipment and microbial technologies are expected to dominate the manufacturing environment and become the “hallmark” of biopharmaceutical manufacturing. Biologicals have potential to reach up to 50% share in global pharmaceutical market in the next few years.

 Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars. Also, the Indian biotechnology industry is also gaining momentum, the biosimilars sector is predicted to treble in value in the next five years, from $481 million in 2011 to $1.4 billion in 2016. More than 20 biosimilar companies are currently operating in India, with around 55 products already on the market. India is one of the leading contributors in the world biosimilar market and is the third-largest in the Asia-Pacific region, after Australia and China.

 The recent establishment of regulatory guidelines for biosimilars in India is expected to add further momentum to the growth of the global biosimilars market. Increasing pressure from governments and insurers for greater biologic competition, there exists an incredible opportunity for biosimilar producers to capitalise on what is set to become the fastest growing sector of the pharmaceutical industry. Due to the limited clinical database at the time of approval of a biosimilar, vigorous pharmacovigilance is required. & Biosimilars are set to become an important part of the future medicines market.

 The Conference will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. Hence, this 3rd Biosimilars Congregation 2013 will look at the multiple facets of biosimilars, ranging from the evolving regulatory landscape and challenges in clinical development, to the legal and economic aspects. By attending this conference you will gain a comprehensive outlook on the key issues surrounding biosimilars. This event will provide an important platform for Biosimilars stakeholders to discuss and share best practices in expediting Biosimilars development.
 
To know more about the conferences 3rd Biosimilars Congregation 2013

Conference on Smart Device and Content 2013

Smart Device and Content 2013 To be held on 19th March 2013 at Eros Hilton Hotel (Nehru Place), New Delhi, India

 The Indian Smart device market is vibrant, with healthy competition and varied offerings in all segments of the market. The volume mix is also shifting towards the mid to high tiers as the replacement market starts to pick up steam. The Indian telecommunications industry is one of the fastest growing in the world and India is projected to become the second largest telecom market globally. http://www.companyprofilesandconferences.com/seminars-conferences/Mobile-Telecoms-c14/Smart-Device-and-Content-2013.html

 India is the second largest mobile handset market in the world after China. The total number of mobile subscribers has hit a high of 771.18 million in India and reaching it to 1000 million by the year 2014. According to a research, the mobile handset market’s revenue is expected to rise from Rs 25,591 crore (Rs 255.91 billion) in 2010 to Rs 35,005 crore (Rs 350.05 billion) in 2016. Wireless Expertise expresses that by 2013 smartphone penetration will be approaching approximately 28-30% of the total mobile market in 2013.

 A high level meeting like Smart Device and Content 2013 will be very influential in building new benchmarks in the device technology. The seminar will help in strategizing a strong vision for smart device landscape in India, as it is an ideal stage between the key influencers and decision makers under one crown. The legendary industry professionals from across the world would share their knowledge. Don't miss this fantastic opportunity to experience new revenue generating strategies and learn innovative business models.

 KEY THEMES DISCUSSED AT THIS CONFERENCE:-

 Smart devices as a platform is thriving and several industry verticals are exploding
 Why smart content players will own devices?
 Smart devices, mobile Internet-based content shaping consumer electronics
 Examining what type of innovative services to be offered for most appealing customers.
 Update on market strategies to inspire user on using the advanced tablets.
 Learn from the leading operators, handset manufacturers, content providers and application developers in the Indian market
 How big a player is Open Source? What further implications can this opportunity drive?
 What new solutions can enable empowerment for the masses from frugal/grassroot to more sophisticated mature solutions that are being brought on by digitization
 Applications and Content are now the largest contributors for innovation and differentiation, how can we leverage the domain to become more effective
 Operators run risk of becoming mere data ‘dumb’ pipes–Can they become ‘smart’ pipes to survive?
 Consumer perception of what is “cool” & “desirable” is rarely connected to the operator brand – Internet companies capture the consumers mindshare
 The Future of Mobile Operating Systems and Frameworks
 Smart devices and the cloud: solutions and security concerns
 What are the roles of vendors - who need to understand what features service providers need and tune them in the Indian environment.
 Identifying the major expectations of handset manufacturers for introducing the innovative MVAS
 Explore effective marketing strategies for upgrading customers from traditional devices
 Examining the current regulation of smart device market in India
 How is the future for the smart devices industry: a vision for 2015
 Be part of a major networking opportunity

 For more information kindly visit :  http://www.companyprofilesandconferences.com/seminars-conferences/Mobile-Telecoms-c14/Smart-Device-and-Content-2013.html                          

 Or

 Contact us at :

 Company Profiles And Conferences
 Phone: +91 22 27810772, 27810773
 Fax: +91 22 27810778
 Email : info@companyprofilesandconferences.com
 Website : www.companyprofilesandconferences.com/
 Our Blogs : http://www.companyprofilesandconferences.com/blog/

Conference 4th Pharmacovigilance 2013

CompanyProfileandconferences.com promote a new conference on "4th Pharmacovigilance 2013" gives information about Latest developments in pharmacovigilance, drug safety and risk management to ensure safer drugs to market.

Conference on 4th Pharmacovigilance 2013 To be held on 12th to13th March 2013 at Hotel Marriott, London UK

CONFERENCE INTRODUCTION:-

It is estimated that the average spend on pharmacovigilance is 6% to 13% of a companies total R&D. From product development in clinical trials to post marketing surveillance, adverse drug reactions are monitored and safety signals investigated. The new legislation includes sweeping changes that leave industry with a lot of questions. If you want to file your product in Europe (MAA), what new PV regulatory processes do you need to put in place? Will the Pharmacovigilance System Master File be useful? And what is really meant by a Quality Management System?

The Conference will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the ke issues of the industry. The entire program will cover the detection, analysis and prevention of adverse drug reactions. It will be studied with the help of case studies and industry experiences.

4th Pharmacovigilance 2013 is the latest in Virtue Insight's series of successful pharmacovigilance events. Also it can help you control your product's lifecycle, your patient's trust, and your revenue. Hence, 4th Pharmacovigilance 2013 will provide an important platform for pharmacovigilance stakeholders to discuss and share best practices in expediting pharmacovigilance Market development.

It gives me great pleasure in welcoming all of you to the Virtue Insight's I wish and pray that all our efforts
will be beneficial to our industries and to our country at large.

KEY THEMES DISCUSSED AT THIS CONFERENCE:-

Exploiting the latest technologies, methodologies and introducing pharmacy automations on work practices of Pharmacovigilance in EU, US and Asia
• Impact of the new European Pharmacovigilance legislation - Implementation and Beyond
• Keeping abreast of the changes impacting the drug safety industry to ensure the pharmacovigilance strategies are robust and geared to compliance
• Recent successful strategies and business models to bring out new medicines
• How will PV activities change with Clinical Trial Transformation Initiative?
• Discover approaches for collecting, integrating and analyzing all of the safety data generated from preclinical models
• Identifying essential antidote requirements and learn to implement best practices in drug safety and surveillance
• Exploiting the pharmacy automations and technologies for enhancement of medication safety
• Impact of technology – learn and explore
• Latest developments in pharmacovigilance, drug safety and risk management to ensure safer drugs to market
• Improving patient care and safety in relation to use of medicines and all medical and paramedical interventions
• Determining the steps and strategies for enhancing quality in healthcare

For more information kindly visit :  4th Pharmacovigilance 2013                       

Or

Contact us at :

Company Profiles And Conferences
Phone : + 91 22 27812707
Fax : + 91 22 27812290
E-mail : info@companyprofilesandconferences.com
Website : www.companyprofilesandconferences.com
 

Conference on 2nd Biosimilars Congregation 2013

CompanyProfileandconferences.com promote a new conference on "2nd Biosimilars Congregation 2013" which discuss on Commercial challenges, opportunities and strategies to develop Biosimilars.

 2nd Biosimilars Congregation 2013 To be held on 19th and 20th Feb 2013 at Marriott Hotel , London UK

 According to Global Industry Analysts Inc.. The global market for biosimilars is forecast to reach US$4.8 billion by the year 2015. By 2020, some $55 Billion worth of biologic patents are due to expire. Key factors driving market growth include patent expiries of key biological drugs, cost containment measures from governments, aging population, and supporting legislations. The recent establishment of regulatory guidelines for biosimilars in the US is expected to add further momentum to the growth of the global biosimilars market. Increasing pressure from governments and insurers for greater biologic competition, there exists an incredible opportunity for biosimilar producers to capitalise on what is set to become the fastest growing sector of the pharmaceutical industry. http://www.companyprofilesandconferences.com/seminars-conferences/Pharmaceuticals-Healthcare-c13/2nd-Biosimilars-Congregation-2013.html

 The barriers to entry for this lucrative market however require that companies establish and harmonise carefully planned regulatory, clinical and marketing strategies. Innovators and biosimilar applicants need to find answers to the current myriad of commercialisation questions that face the market. Those to establish their market presence first will dictate the success of companies in the biosimilar space.

 Europe holds the highest number of biosimilar approvals, and this number will continue to increase in the near future. Further biologic patent expiries will boost the number of biosimilars to be approved, thereby bringing in an increased number of products that will help increase market size and competition among market participants. The biosimilars market is in the nascent stage of the industry life cycle with limited market and product development experience. However, there is a significant market opportunity from patent expiries. High initial investments are still a major barrier for new entrants. Collaborations among large pharmaceutical companies with financial capabilities and specialty biotech companies with technical expertise are expected. The strong integration of marketing and research and development skills is the key to success in the biosimilars market.

 The Conference will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. Hence, this 3rd Biosimilars Congregation 2013 will look at the multiple facets of biosimilars, ranging from the evolving regulatory landscape and challenges in clinical development, to the legal and economic aspects. By attending this conference you will gain a comprehensive outlook on the key issues surrounding biosimilars. This event will provide an important platform for Biosimilars stakeholders to discuss and share best practices in expediting Biosimilars development.

 Key Speakers Include:-
 Paul Tredwell, Head of Biopharmaceuticals, Sandoz
 Anne Cook, Biologicals Quality Assessor, MHRA
 Cecil Nick, Vice President, Biotechnology, Parexel
 Yariv Hefez, Vice President Business Development & Alliance Management, Biosimilars, Merck Serono
 Alex Kudrin, Medical Assessor in Licensing of Biological Products, MHRA (Former Medical Director,Takeda Pharmaceuticals )
 Malcolm I Mitchell, Senior Medical Fellow, Clinical Pharmacology, Eli Lilly

 For more information kindly visit :  http://www.companyprofilesandconferences.com/seminars-conferences/Pharmaceuticals-Healthcare-c13/2nd-Biosimilars-Congregation-2013.html                         

 Or

 Contact us at :

 Company Profiles And Conferences
 Phone: +91 22 27810772, 27810773
 Fax: +91 22 27810778
 Email : info@companyprofilesandconferences.com
 Website : www.companyprofilesandconferences.com/
 Our Blogs : http://www.companyprofilesandconferences.com/blog/